Home / Publications / [161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors

[161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors

, 
Bayirta Vladimirovna Egorova 1
Bayirta Vladimirovna Egorova
,  ,  , 
Ramiz Avtandilovich Aliev 1, 2
Ramiz Avtandilovich Aliev
, 
Galina Aronovna Posypanova 2
Galina Aronovna Posypanova
, 
Anna Borisovna Priselkova 1
Anna Borisovna Priselkova
, 
Anton V. Kolotaev 2, 3
Anton V. Kolotaev
, 
Derenik Sarkisovich Khachatryan 2, 3
Derenik Sarkisovich Khachatryan
, 
Vasily N Osipov 4
Vasily N Osipov
, 
Stepan Nikolaevich Kalmykov 1, 2
Stepan Nikolaevich Kalmykov
1 Department of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russian Federation
2 National Research Centre 'Kurchatov Institute', Moscow, Russian Federation
3 Institute of Chemical Reagents and High Purity Chemical Substances, National Research Centre 'Kurchatov Institute', Moscow, Russian Federation
4 N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
10.1016/j.mencom.2023.06.009
Published 2023-06-13
Communication , Volume 33, Issue 4, 469-471
5
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Fedotova A. O. et al. [161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors // Mendeleev Communications. 2023. Vol. 33. No. 4. pp. 469-471.
GOST all authors (up to 50) Copy
Fedotova A. O., Egorova B. V., Aleshin G. Y., Zamurueva L. S., Aliev R. A., Posypanova G. A., Priselkova A. B., Kolotaev A. V., Khachatryan D. S., Osipov V. N., Kalmykov S. N. [161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors // Mendeleev Communications. 2023. Vol. 33. No. 4. pp. 469-471.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2023.06.009
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2023.06.009
TI - [161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors
T2 - Mendeleev Communications
AU - Fedotova, Anzhelika Olegovna
AU - Egorova, Bayirta Vladimirovna
AU - Aleshin, Gleb Yuryevich
AU - Zamurueva, Lyubov Sergeevna
AU - Aliev, Ramiz Avtandilovich
AU - Posypanova, Galina Aronovna
AU - Priselkova, Anna Borisovna
AU - Kolotaev, Anton V.
AU - Khachatryan, Derenik Sarkisovich
AU - Osipov, Vasily N
AU - Kalmykov, Stepan Nikolaevich
PY - 2023
DA - 2023/06/13
PB - Mendeleev Communications
SP - 469-471
IS - 4
VL - 33
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2023_Fedotova,
author = {Anzhelika Olegovna Fedotova and Bayirta Vladimirovna Egorova and Gleb Yuryevich Aleshin and Lyubov Sergeevna Zamurueva and Ramiz Avtandilovich Aliev and Galina Aronovna Posypanova and Anna Borisovna Priselkova and Anton V. Kolotaev and Derenik Sarkisovich Khachatryan and Vasily N Osipov and Stepan Nikolaevich Kalmykov},
title = {[161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors},
journal = {Mendeleev Communications},
year = {2023},
volume = {33},
publisher = {Mendeleev Communications},
month = {Jun},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2023.06.009},
number = {4},
pages = {469--471},
doi = {10.1016/j.mencom.2023.06.009}
}
MLA
Cite this
MLA Copy
Fedotova, Anzhelika Olegovna, et al. “[161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors.” Mendeleev Communications, vol. 33, no. 4, Jun. 2023, pp. 469-471. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2023.06.009.

Keywords

161Tb.
neuroendocrine tumors
peptide receptor radionuclide therapy
short peptides
somatostatin analogs

Abstract

Thz-Phe-D-Trp-Lys-Thr-DOTA, a conjugate of the DOTA chelator and the Thz-Phe-D-Trp-Lys-Thr pentapeptide, was labeled with 152Eu and 161Tb radionuclides, where 161Tb has decay characteristics suitable for its use in cancer therapy. For the [152Eu]Eu-Thz-Phe-D-Trp-Lys-Thr-DOTA complex, the biodistribution in nude mice bearing IMR-32 tumors was evaluated for the first time. It was shown that the complexes of the conjugate demonstrate accumulation in the tumor at the level of DOTA-TATE, another peptide conjugate widely used in nuclear medicine for the diagnosis and therapy of neuroendocrine tumors, which allows Thz-Phe-D-Trp-Lys-Thr-DOTA to be considered as a potential biological vector for radiopharmaceuticals.

References

.
From octreotide to shorter analogues: Synthesis, radiolabeling, stability
Yakusheva A., Titchenko N., Egorova B., Matazova E., Podkhalyuzina N., Osipov V., Khachatryan D., Avdeev D., Posypanova G., Kalmykov S.
Journal of Labelled Compounds and Radiopharmaceuticals, 2019
.
Labeling and receptor affinity of an ultra-short somatostatin analogue Thz-Phe-D-Trp-Lys-Thr-DOTA
Fedotova A.O., Egorova B.V., Posypanova G.A., Titchenko N.A., Khachatryan D.S., Kolotaev A.V., Osipov V.N., Kalmykov S.N.
Journal of Peptide Science, 2021
.
A potent cyclic hexapeptide analogue of somatostatin
Veber D.F., Freidinger R.M., Perlow D.S., Paleveda W.J., Holly F.W., Strachan R.G., Nutt R.F., Arison B.H., Homnick C., Randall W.C., Glitzer M.S., Saperstein R., Hirschmann R.
Nature, 1981
.
The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy
Lehenberger S., Barkhausen C., Cohrs S., Fischer E., Grünberg J., Hohn A., Köster U., Schibli R., Türler A., Zhernosekov K.
Nuclear Medicine and Biology, 2011
.
Somatostatin and Its Receptor Family
Patel Y.C.
Frontiers in Neuroendocrinology, 1999
.
Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
Müller C., Reber J., Haller S., Dorrer H., Bernhardt P., Zhernosekov K., Türler A., Schibli R.
European Journal of Nuclear Medicine and Molecular Imaging, 2013
.
Yttrium-90 DOTATOC: first clinical results
Otte A., Herrmann R., Heppeler A., Behe M., Jermann E., Powell P., Maecke H.R., Muller J.
European Journal of Nuclear Medicine and Molecular Imaging, 1999
.
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R.
Science, 1973
.
Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
Kunikowska J., Zemczak A., Kołodziej M., Gut P., Łoń I., Pawlak D., Mikołajczak R., Kamiński G., Ruchała M., Kos-Kudła B., Królicki L.
European Journal of Nuclear Medicine and Molecular Imaging, 2020
.
Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
Gracheva N., Müller C., Talip Z., Heinitz S., Köster U., Zeevaart J.R., Vögele A., Schibli R., van der Meulen N.P.
EJNMMI Radiopharmacy and Chemistry, 2019
.
Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
Reubi J., Waser B., Schaer J., Laissue J.A.
European Journal of Nuclear Medicine and Molecular Imaging, 2001
.
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Otte A., Mueller-Brand J., Dellas S., Nitzsche E., Herrmann R., Maecke H.
The Lancet, 1998
.
Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels
Reubi J.C., Schaer J., Laissue J.A., Waser B.
Metabolism: Clinical and Experimental, 1996
.
First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
Baum R.P., Singh A., Kulkarni H.R., Bernhardt P., Rydén T., Schuchardt C., Gracheva N., Grundler P.V., Köster U., Müller D., Pröhl M., Zeevaart J.R., Schibli R., van der Meulen N.P., Müller C., et. al.
Journal of Nuclear Medicine, 2021
.
Targeted nuclear medicine. Seek and destroy
Tolmachev V.M., Chernov V.I., Deyev S.M.
Russian Chemical Reviews, 2022